£2m Deltex US, German growth:
This article was originally published in Clinica
UK haemodynamic monitoring company Deltex Medical is looking to expand its sales and marketing operations in the US and Germany with £2m ($4m) of new capital it has secured. The funds, provided in the form of an equity investment-and-loan package, will come from US private equity firm Nexus Medical Partners, and its German affiliate Medicis Capital Partners. Deltex will use the financing to hire additional management and sales staff for its operations in US and Germany. The countries represent the two largest potential markets for the company's CardioQ monitor, according to Chichester, West Essex-based Deltex.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.